Is there any Royal College guidance for the long-term use of GnRH analogues, i.e., more than 6 months, in endometriosis or uterine fibroids?

This review investigated the existence of Royal College guidance regarding the long-term administration of GnRH analogues for more than six months in patients with endometriosis or uterine fibroids. The authors found no direct evidence of specific Royal College guidelines addressing this extended duration of therapy. Instead, indirect sources highlight the necessity of careful clinical management, particularly the use of add-back therapy to mitigate adverse side effects associated with prolonged treatment. Relevance to endometriosis: listed as one indication for GnRH antagonists, though the paper's main focus is uterine fibroids.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works